Skip to main content

Table 1 Baseline characteristics

From: Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial

Baseline characteristics

Treatment group

ASMQ + Pq

CQ + Pq

AL + Pq

N (%)

88 (33.3%)

88 (33.3%)

88 (33.3%)

Study site

 CEPEM

66 (75.0%)

66 (75.0%)

66 (75.0%)

 FMT-HVD

22 (25.0%)

22 (25.0%)

22 (25.0%)

Gender

 Female

32 (36.4%)

22 (25.0%)

24 (27.3%)

 Male

56 (63.6%)

66 (75.0%)

64 (72.7%)

Age (years)

 > 59

3 (3.4%)

4 (4.5%)

3 (3.4%)

 18–39

45 (51.1%)

34 (38.6%)

49 (55.7%)

 39–59

40 (45.4%)

50 (56.8%)

36 (40.9%)

Weight (kg)

 > 80

25 (28.4%)

22 (25.0%)

27 (30.7%)

 50–65

27 (30.7%)

21 (23.9%)

23 (26.1%)

 65–80

36 (40.9%)

45 (51.1%)

38 (43.2%)

Fever

 < 37.5

48 (54.5%)

54 (61.4%)

53 (60.2%)

 > 37.5

40 (45.4%)

34 (38.6%)

35 (39.8%)

Weight (kg)

71.59 (10.99)

[51–90]

72.7 (10.34)

[53–90]

72.53 (10.59)

[50–90]

Temperature

37.45 (1.38)

[34.7–40.5]

37.31 (1.21)

[35.0–39.9]

37.38 (1.22)

[35.2–40.6]

Parasitaemia

2145 (2516.4)

[258–13,340]

2155 (2908.5)

[285–17,680]

2444 (3974.6)

[270–20,080]

Age (years)

38.75 (10.9)

[19.5–65.8]

41.88 (10.5)

[19.7–64.9]

37.24 (11.8)

[18.4–64.3]

  1. Absolute number and percentage (%) were used to present categorical variables. Quantitative data presented using means, standard deviations (SD), and ranges [min–max]. Parasitaemia presented using geometric mean